FDA GUIDANCE DOCUMENT: Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations

Explains how FDA determines whether two human gene therapy products are the “same drug” for purposes of orphan-drug designation and the 7-year orphan-drug exclusivity. If a previously approved product has orphan exclusivity, FDA generally may not approve a later application for the same drug for the same indication unless the later product is clinically superior (greater efficacy, greater safety, or a major contribution to patient care).

Applies to human gene therapy products reviewed by CBER and OOPD for orphan designation and exclusivity decisions.

Under 21 CFR 316.3(b)(14)(ii), FDA evaluates principal molecular structural features of the products. For gene therapies, FDA generally considers the transgene and the vector generally considered the defining features, though FDA may also evaluate other product features when relevant.

Transgene: If products express different transgenes, FDA generally considers them different drugs, regardless of whether the vector is the same or different. Minor differences (e.g., polymorphisms) may not make them different; FDA evaluates that case-by-case.

Vector: If products use different vectors, FDA generally considers them different drugs—whether or not the transgene is the same.

Vectors from different viral groups (e.g., gammaretrovirus vs AAV) → different.

Even within the same viral group (e.g., AAV2 vs AAV5), FDA generally considers them different when differences are likely to affect tropism, immune-response avoidance, or insertional mutagenesis risk.

Variants of a vector (e.g., AAV2 vs an AAV2 variant) may be judged same or different case-by-case.

Additional features (when transgene and vector are the same): FDA may consider other features of the final product that contribute to therapeutic effect—e.g., regulatory elements (promoters, enhancers, splicing elements) or, for ex vivo products, the cell type, though these features are usually secondary to transgene/vector and evaluated case-by-case.

Clinical superiority as a path to approval
If a later gene therapy is deemed the same drug as one with orphan exclusivity for the same indication, it may still be approved if the sponsor demonstrates clinical superiority (greater efficacy, greater safety, or a major contribution to patient care).